Search Results
Your search for The ASCO matches 20054 pages
Showing 1 - 50A Delay in Diagnosis Led to Advanced Prostate Cancer
Cancer is not an unfamiliar disease to me. My mother died of cancer when I was 12. My oldest sister died of breast cancer, an aunt died of cancer (I don’t know which type), and my older brother is a prostate cancer survivor. So, when I was diagnosed with prostate cancer in October 2021, the news...
NIH’s New Cancer Screening Research Network and Cancer Screening Technologies
The National Institutes of Health (NIH) has launched the Cancer Screening Research Network, a clinical trials network to evaluate emerging cancer screening technologies. The new network will support the Biden-Harris Administration’s Cancer Moonshot initiative by investigating how to identify cancer ...
Novel PET Agent May Accelerate Imaging in Patients With Clear Cell Renal Cell Carcinoma
The novel investigational positron-emission tomography (PET) imaging agent gallium (Ga)-68–DPI-4452 may offer rapid and accurate visualization of lesions in patients with clear cell renal cell carcinoma, according to a recent study published by Hofman et al in The Journal of Nuclear Medicine. The...
Chemical-Related Epigenetic Modifications May Increase Risk of Prostate Cancer Among Firefighters
Exposure to certain chemicals while on the job may increase the risk of prostate cancer among firefighters, according to a recent study published by Quaid et al in Environmental and Molecular Mutagenesis. Background Prostate cancer has the highest incidence of any cancer type among U.S. male...
New Policy Statement Addresses Social, Economic, and Environmental Factors Influencing Cancer Care, Outcomes
ASCO’s new policy statement highlights the need for formalized efforts to address health-related social needs and outlines ways to address social determinants of health (SDOH) in cancer care. Social determinants are defined as conditions in which people are born, grow, live, work, and age, which...
America’s Cancer Doctors Demand Action From Congress: Address Drug Shortages
Cancer doctors from across the United States are lending their voices to a new advocacy campaign to end drug shortages. Led by the Association for Clinical Oncology (ASCO), nearly 500 oncology professionals have signed an open letter to Congress and the administration highlighting the severe impact ...
Bishoy Faltas, MD, Named Chief Research Officer of the Englander Institute for Precision Medicine at Weill Cornell Medicine
Olivier Elemento, PhD, Director of the Englander Institute for Precision Medicine (EIPM) at Weill Cornell Medicine, New York, recently announced that Bishoy M. Faltas, MD, has been named Chief Research Officer of EIPM effective immediately. EIPM is a large multidisciplinary institute that uses...
AI in Cancer Care: Embrace the Change
According to Google Chief Executive Officer Sunder Pichai, artificial intelligence (AI) is “the most profound technology humanity is working on—more profound than fire or electricity or anything that we’ve done in the past.” The impact of AI on health care and especially cancer care will not be...
ASCO Survey Finds Oncologists’ Well-Being Worsened Over the Past Decade—but Steps Can Be Taken to Mitigate Burnout
A recent survey by ASCO measuring postpandemic burnout among oncologists in the United States shows that professional satisfaction and work-life balance have significantly deteriorated over the past decade, with 59% of respondents reporting one or more symptoms of burnout, compared with 34% in...
Two Studies Support Deintensification of Treatment for HPV-Associated Oropharyngeal Cancer
Two studies presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium added support for the deintensification of radiotherapy in early-stage oropharyngeal squamous cell cancers associated with the human papillomavirus (HPV), a subtype typically more responsive to therapy compared to...
Historical Community Outreach and Engagement Efforts at NCI-Designated Cancer Centers
Investigators have examined the historical evolution of Community Outreach and Engagement initiatives at the National Cancer Institute (NCI) and NCI-designated cancer centers and provided recommendations to guide future efforts, according to a recent study published by Pohl et al in CA: A Cancer...
Newly Identified Biomarkers May Improve Diagnosis and Treatment of RCC Subtypes
Researchers have identified novel biomarkers in renal cell carcinoma subtypes, according to a new study published by Li et al in Cell Reports Medicine. The findings may help identify therapeutic targets in non–clear cell renal cell carcinomas. Background Renal cell carcinoma is a diverse cancer...
Effect of Radiation Therapy Timing on Lifespan of Artificial Urinary Sphincters in Prostate Cancer Survivors
Researchers have shown that adjuvant radiation therapy rather than salvage radiation therapy may improve the function of artificial urinary sphincters for stress urinary incontinence in patients who have undergone surgery for prostate cancer, according to new findings presented by Gaines et al at...
Bavituximab Plus Pembrolizumab for Patients With Hepatocellular Carcinoma
Adding the phosphatidylserine-targeting antibody bavituximab to the immunotherapy agent pembrolizumab may improve response rates without compromising safety in patients with hepatocellular carcinoma, according to a recent study published by Hsieh et al in Nature Communications. The findings...
Breast-Conserving Therapy in BRCA-Mutation Carriers: Study Looks at Long-Term Outcomes
Recent research has provided valuable insights into the long-term outcomes of patients with pathogenic BRCA1 and BRCA2 mutations who undergo breast-conserving therapy, according to a study presented at the 2024 Society of Surgical Oncology (SSO) Annual Meeting.1 The observational study found that...
Improving AML Outcomes: Testing for MRD Prior to Bone Marrow Transplant
Testing for measurable residual disease (MRD) prior to bone marrow transplant may be effective and practical in patients in remission after receiving treatment for acute myeloid leukemia (AML), according to a recent study published by Dillon et al in JAMA Oncology. Study Methods and Results In the...
AI Model May Accurately Predict Mental Health Outcomes in Patients With Cancer
A novel artificial intelligence (AI) model may accurately predict which patients with cancer may require mental health services during cancer care, according to a recent study published by Nunez et al in Communications Medicine. Background Mental health has been shown to have a significant impact...
Smoking Cessation Regimens: Does Dose of Therapy Matter?
Altering or increasing the dosages of smoking cessation regimens may help patients quit smoking, according to a recent study published by Cinciripini et al in JAMA. The findings indicated that the smoking cessation drug varenicline may be more effective than combined nicotine replacement therapy...
Preferred Sites of Cancer Care: Community Oncology Practices vs Hospitals and Academic Centers
Investigators uncovered that community oncology practices emerged as the preferred sites of service for cancer treatment compared with hospitals and academic centers, according to a recent case study. The findings may challenge the common perception of hospitals and academic centers as preferable...
Effect of Mindfulness Audio Recordings on Physical, Emotional Side Effects During Radiation Therapy for Prostate Cancer
Listening to mindfulness audio recordings may effectively alleviate the side effects of radiation therapy in men with prostate cancer, according to a recent study published by Victorson et al in Global Advances in Integrative Medicine and Health. Background Men with prostate cancer who receive...
Mortality Trends Among Asian American, Native Hawaiian, and Other Pacific Islander Patients With Preventable Cancers
The American Cancer Society (ACS) has detailed disparities in the mortality rates for preventable cancer types among Asian American, Native Hawaiian, and other Pacific Islander patients in a new Cancer Facts & Figures report published by Wagle et al. Background In this report, the Asian...
Glecirasib Shows Efficacy and Safety in KRAS G12C–Mutated NSCLC
Glecirasib monotherapy demonstrated efficacy in previously treated patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC) according to data presented during the ASCO Plenary Series: April 2024 Session (Abstract 468214). Results of the pivotal Chinese phase II study of glecirasib...
Pasi A. Jänne, MD, PhD, on NSCLC, Osimertinib, Chemotherapy: Update From FLAURA2
Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, discusses an exploratory analysis from the FLAURA2 study, which indicates that baseline levels of plasma EGFR mutation may be prognostic and predictive of clinical benefit with osimertinib plus chemotherapy vs osimertinib alone for patients...
Cancer Screening Rates May Be Significantly Lower in U.S. Federally Qualified Health Centers
The rates of breast, cervical, and colorectal cancer screenings in Federally Qualified Health Centers may be substantially lower compared with overall screening rates in the United States, according to a recent study published by Amboree et al in JAMA Internal Medicine. Background The U.S....
Aspirin Use Among Breast Cancer Survivors: Navigating Negative Results, Age, and Health Equity
Investigators uncovered critical issues related to health equity and aging that may have broad implications for cancer trials among breast cancer survivors receiving aspirin, according to a recent study published by Mandelblatt et al in JAMA. Study Methods and Results In the recent study, the...
Kelly K. Hunt, MD, on Breast Cancer and Neoadjuvant Therapy: Expert Commentary
Kelly K. Hunt, MD, of The University of Texas MD Anderson Cancer Center, discusses the benefits to patients with neoadjuvant therapy in advanced, inoperable breast cancer, for whom this treatment works best, and novel approaches currently under investigation.
USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer
Today, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for breast cancer. The USPSTF now recommends that all women get screened for breast cancer every other year starting at age 40 and continuing through age 74 (B grade recommendation). More ...
FDA Approves Trastuzumab Biosimilar Trastuzumab-strf
The U.S. Food and Drug Administration (FDA) has approved trastuzumab-strf (Hercessi), a biosimilar to trastuzumab (Herceptin), for the treatment of HER2-overexpressing breast cancer and gastric or gastroesophageal junction adenocarcinoma. Trastuzumab-strf is indicated for adjuvant treatment of...
FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer
On April 29, the U.S. Food and Drug Administration (FDA) granted traditional approval to tisotumab vedotin-tftv (Tivdak) for patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy. Tisotumab vedotin-tftv previously received accelerated approval for...
Combination of Preketone Supplements and Immunotherapy May Be Effective in Patients With Prostate Cancer
The addition of a component of the ketogenic diet—a preketone dietary supplement—to immunotherapy showed efficacy in potentially treating prostate cancer in a laboratory setting, according to a recent study published by Murphy et al in Cancer Research. Background Although immune checkpoint blockade ...
Trends in Hematopoietic Cell Transplantation Survival Rates Across Racial and Ethnic Groups
The rate of survival following autologous and allogeneic hematopoietic cell transplantation may have increased among all racial and ethnic groups, but disparities may still exist among some patient groups, according to a recent study published by Khera et al in Blood Advances. Background Autologous ...
AUA, ASCO, and SUO Publish 2024 Amendment to Nonmetastatic Muscle-Invasive Bladder Cancer Guidelines
The American Urological Association (AUA), in partnership with ASCO and the Society of Urologic Oncology (SUO), has issued a 2024 clinical practice guideline amendment for the diagnosis and treatment of nonmetastatic muscle-invasive bladder cancer. The updated guidelines were published by...
Barriers to Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
Investigators have uncovered persistent racial and social disparities that may impede access to autologous hematopoietic cell transplantation for some patients with multiple myeloma, according to a recent study published by Esteghamat et al in Clinical Lymphoma, Myeloma & Leukemia. Background...
Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care
The current body of research may inadequately address the intersection of aging, health disparities, and cancer outcomes among older patients, according to a recent systematic review published by Gilmore et al in the Journal of the American Geriatrics Society. The findings revealed an urgent need...
Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being
Investigators have uncovered that the emotional and physical health of breast cancer survivors may be influenced by their relationship with their partners, according to a recent study published by Vachon et al in Healthcare. Background The diagnosis and treatment of breast cancer often place...
Douglas B. Johnson, MD, MSCI, on Cutaneous Melanoma: Treatment Updates
Douglas B. Johnson, MD, MSCI, of Vanderbilt-Ingram Cancer Center, discusses updated guidelines on the use of neoadjuvant therapy, as well as first- and later-line systemic therapies to treat patients with cutaneous melanoma.
Pamela Kunz, MD, Named Editor-in-Chief of New JCO Oncology Advances
ASCO recently announced the upcoming launch of JCO Oncology Advances (JCO OA), a new open-access and interdisciplinary journal. Pamela Kunz, MD, will serve as the new Editor-in-Chief of this innovative journal, dedicated to accelerating progress in the global fight against cancer by providing a...
Rapid Guideline Update Supports Capivasertib for Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer now have a new medication option that extends survival, according to an ASCO rapid guideline update.1 The update was designed to orient clinicians to outcomes from the CAPItello-291 trial, which led to the U.S. Food...
Breast Cancer Stalked My Family for Generations and Finally Came for Me
My maternal grandmother, mother, and two of my mother’s sisters were all diagnosed with breast cancer when they were relatively young, so I figured one day, the disease would come for me. Breast cancer is the most common cancer diagnosed among Alaska Native women,1 and at a very early age, my...
AI Model May Help Predict Treatment Responses, Select Most Effective Cancer Therapies in Patients With Cancer
Researchers have developed a novel artificial intelligence (AI) model that may accurately predict whether patients with cancer will respond to certain therapies, according to a recent study published by Sinha et al in Nature Cancer. The findings indicated that single-cell RNA sequencing data may be ...
Advanced-Stage Classical Hodgkin Lymphoma
Classical Hodgkin lymphoma (HL) is a highly curable disease, but up to 25% of patients will develop relapsed or refractory classical HL. Although most patients achieve complete response following front-line therapy, key unmet clinical needs include reducing the relapse rate, decreasing acute and...
Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved
Recently, the U.S. Food and Drug Administration (FDA) approved pegulicianine (Lumisight) for adult patients with breast cancer to assist in the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy. Pegulicianine is a...
FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs
On April 23, the U.S. Food and Drug Administration (FDA) approved lutetium Lu-177 dotatate (Lutathera) for pediatric patients aged 12 years and older with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut...
Potential Protective Effects of Aspirin Against Colorectal Cancer
Researchers may have uncovered how the long-term daily use of aspirin may help prevent the development and progression of colorectal cancer, according to a recent study published by De Simoni et al in Cancer. Study Methods and Results In the recent study, the researchers collected the tissue...
FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
On April 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the type II RAF inhibitor tovorafenib (Ojemda) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement or BRAF V600 mutation. This...
Wendy Vogel, MSN, FNP, AOCNP, FAPO, on the Evolving Role of Advanced Practice Providers in Oncology Care
Wendy Vogel, MSN, FNP, AOCNP, FAPO, of the Advanced Practitioner Society for Hematology and Oncology, summarizes a panel discussion in which she took part, on forming interprofessional oncology care teams that include advanced practitioners. Such collaboration may improve patient outcomes and help...
FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer
On April 22, the U.S. Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva) with bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors. QUILT-3.032 Trial Efficacy...
Predicting Ovarian Cancer Relapse With Spatial Tissue Analysis
Researchers have found that spatial tissue analysis may help predict early posttreatment relapse and illuminate new potential therapies in patients with high-grade serous ovarian carcinoma, according to a recent study published by Xu et al in Science Advances. Background Many patients with...
Chemohormonal Therapy for Locally Advanced Prostate Cancer
A neoadjuvant chemohormonal therapy combination may offer extended control of prostate-specific antigen (PSA) levels in patients with locally advanced prostate cancer compared with hormonal therapy alone, according to a recent study published by Qian et al in The Journal of Urology. Background...
Propofol-Based Anesthesia May Offer Improved Detection of Serrated Polyps During Colonoscopy
Deeper sedation with the anesthetic drug propofol may improve detection of serrated polyps in patients undergoing colonoscopy to screen for colorectal cancer, according to a recent study published by Quaye et al in Anesthesiology. Background Nearly all colorectal cancers start as polyps....
